Shots:

• Evaxion to receive up front & is eligible to receive the milestones along with the sub-licensing royalty. Both companies will equally share 50/50 research and IP licensing costs through 2025 with all costs included in each party’s existing operating expenses
• Under a development and commercialization agreement, ExpreS²ion gets an exclusive right to license the CMV vaccine candidate. Additionally, the collaborative discovery project will be a part of Evaxion's EVX-V1 development pipeline
• The collaboration focuses to design a next-generation vaccine candidate that elicits both cellular and humoral/antibody responses by using Evaxion’s AI platform, RAVEN

Ref: Globenewswire | Image: Evaxion